However, this inference has not yet been proved, and future randomized controlled trials with large sample sizes are required to clarify the prognostic value and efficacy of PARP expression in predicting PARP inhibitor therapy outcome in breast cancer. This evidence concerns the gene PARP1 and breast carcinoma.